Factors explaining socio-economic inequalities in cancer survival: a systematic review
Background: There is strong and well-documented evidence that socio-economic inequality
in cancer survival exists within and between countries, but the underlying causes of these …
in cancer survival exists within and between countries, but the underlying causes of these …
[HTML][HTML] Access to therapy for acute myeloid leukemia in the developing world: barriers and solutions
LA Meillon-Garcia, R Demichelis-Gomez - Current Oncology Reports, 2020 - Springer
Abstract Purpose of Review Acute myeloid leukemia (AML) is a costly disease, and its
impact is greater in developing countries (DC). We will review the current concept of what …
impact is greater in developing countries (DC). We will review the current concept of what …
Poor survival and differential impact of genetic features of black patients with acute myeloid leukemia
B Bhatnagar, J Kohlschmidt, K Mrózek, Q Zhao… - Cancer discovery, 2021 - AACR
Clinical outcome of patients with acute myeloid leukemia (AML) is associated with
cytogenetic and molecular factors and patient demographics (eg, age and race). We …
cytogenetic and molecular factors and patient demographics (eg, age and race). We …
[HTML][HTML] Patterns of undertreatment among patients with acute myeloid leukemia (AML): considerations for patients eligible for non-intensive chemotherapy (NIC)
E Hubscher, S Sikirica, T Bell, A Brown, V Welch… - Journal of Cancer …, 2021 - Springer
Acute myeloid leukemia (AML) is a life-threatening malignancy that is more prevalent in the
elderly. Because the patient population is heterogenous and advanced in age, choosing the …
elderly. Because the patient population is heterogenous and advanced in age, choosing the …
[HTML][HTML] Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia
Inequitable uptake of novel therapies (NT) in non-cancer settings are known for patients with
lower socioeconomic status (SES), People of Color (POC), and older adults. NT uptake …
lower socioeconomic status (SES), People of Color (POC), and older adults. NT uptake …
Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020
H Liu, SJ Stanworth, S McPhail, M Bishton… - Blood …, 2024 - ashpublications.org
Abstract We report 1-and 5-year survival after acute myeloid leukemia (AML) diagnosis and
early mortality within 30 days of systemic anticancer therapy (SACT) treatments, using …
early mortality within 30 days of systemic anticancer therapy (SACT) treatments, using …
Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population‐based study in France
Background The excess mortality observed in Acute Myeloblastic Leukaemia (AML)
patients, partly attributed to unequal access to curative treatments, could be linked to care …
patients, partly attributed to unequal access to curative treatments, could be linked to care …
[HTML][HTML] Increasing access to fertility preservation for women with breast cancer: protocol for a stepped-wedge cluster randomized trial in France
MC Addamiano, C Joannes, L Fonquerne, C Morel… - BMC Public Health, 2024 - Springer
Background With the increase in the number of long-term survivors, interest is shifting from
cancer survival to life and quality of life after cancer. These include consequences of long …
cancer survival to life and quality of life after cancer. These include consequences of long …
[HTML][HTML] The long shadow of socioeconomic deprivation over the modern management of acute myeloid leukemia: time to unravel the challenges
Biological and non-biological variables unrelated to acute myeloid leukemia (AML) preclude
standard therapy in many settings, with “real world” patients under-represented in clinical …
standard therapy in many settings, with “real world” patients under-represented in clinical …
Introducing patient‐reported outcome in the acute leukemia quality registries in Sweden
EB Lennmyr, K Karlsson… - European journal of …, 2020 - Wiley Online Library
Objectives The use of patient‐reported outcome (PRO) measured outside clinical trials is not
well defined. We report the first analysis of the prospective PRO study within the Swedish …
well defined. We report the first analysis of the prospective PRO study within the Swedish …